Abiomed Announces Results of Impella(R) 2.5 FDA PROTECT I Safety Trial for High-Risk PCI Cases (Business Wire via Yahoo! Finance)
DANVERS, Mass.----Abiomed, Inc. formally announced the results of its Impella 2.5 PROTECT I safety trial for the first time at the Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics Scientific Symposium and main sessions.

FDA approves Genzyme's Renvela for dialysis patients (Pharmaceutical Business Review)
The FDA has granted marketing approval to Genzyme for its Renvela treatment for the control of serum phosphorus in patients with chronic kidney disease on dialysis.